You are here:

etravirine (Intelence)

Advice

following an abbreviated submission:

etravirine (Intelence®) is accepted for restricted use within NHS Scotland.

Indication under review: in combination with a boosted protease inhibitor and other antiretroviral medicinal products, for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in antiretroviral treatment-experienced paediatric patients from 6 years to less than 18 years of age.

SMC restriction: to be prescribed under the supervision of specialists in paediatric HIV.

SMC has previously accepted etravirine for use in combination with a boosted protease inhibitor and other antiretroviral medicinal products for the treatment of HIV-1 infection in antiretroviral treatment experienced adult patients. Etravirine is listed in the British National Formulary for Children 2012-2013 for the treatment of HIV infection.

Drug Details

Drug Name: etravirine (Intelence)
SMC Drug ID: 901/13
Manufacturer: Janssen-Cilag Ltd
Indication: In combination with a boosted protease inhibitor and other antiretroviral medicinal products, for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in antiretroviral treatment-experienced paediatric patients from 6 years to less than 18 years of age.
BNF Category:
Sub Category: 5.3 Antiviral Drugs
Submission Type: Abbreviated Submission
Status: Restricted
Date Advice Published: 9 September 2013

Back